Powder: -20°C for 3 years | In solvent: -80°C for 1 year
The quinuclidine PHA 568487 free base is an agonist of the alpha 7 nicotinic acetylcholine receptor that was designed to mitigate the bioactivation associated with the core scaffold and subsequently remove associated liabilities with in vivo tolerability.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
2 mg | 在庫あり | ¥ 8,000 | |||
5 mg | 在庫あり | ¥ 13,000 | |||
10 mg | 在庫あり | ¥ 20,500 | |||
25 mg | 在庫あり | ¥ 39,000 | |||
50 mg | 在庫あり | ¥ 72,000 | |||
100 mg | 在庫あり | ¥ 129,500 | |||
500 mg | 在庫あり | ¥ 271,000 |
説明 | The quinuclidine PHA 568487 free base is an agonist of the alpha 7 nicotinic acetylcholine receptor that was designed to mitigate the bioactivation associated with the core scaffold and subsequently remove associated liabilities with in vivo tolerability. |
別名 | PHA 568487 |
分子量 | 288.34 |
分子式 | C16H20N2O3 |
CAS No. | 527680-56-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30 mg/mL (104.04 mM), Sonication is recommended.
H2O: < 40.44 mg/mL (100mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PHA 568487 free base 527680-56-4 Neuroscience AChR macrophage fracture acetylcholine Inhibitor ischemic bone PHA-568487 receptor cerebral middle Post-stroke PHA 568487 stroke inhibit PHA568487 memory oxidative polarization dysfunction Nicotinic acetylcholine receptors occlusion neuroinflammation nicotinic artery stress nAChR inhibitor